China-Originated Innovation
Out-Licensing from China: Sequencing US, EU, and Japan Conversations
Parallel conversations with US, European, and Japanese partners aren't independent processes. Sequencing them well protects leverage; getting the order wrong gives it away.
These conversations aren't running in parallel, even when they look like it
Term sheet momentum in one region changes how the next conversation opens. A credible US process in motion is the single strongest thing a Chinese licensor can bring into a European or Japanese conversation, and the reverse is just as true if the US process stalls first.
The US conversation carries the compliance load
BIOSECURE screening, HGR export approval, and increasingly BINSA-style review considerations front-load onto the US conversation specifically. Clearing that groundwork before opening US discussions, rather than during them, keeps the timeline from becoming the story.
Japan and Europe follow a different logic
Japanese partners more often want distinct regional rights and a genuine local development partner, not just a licensing counterparty: geographic carve-outs are negotiated as their own structure, not an afterthought to a global deal. European conversations, by contrast, can often move faster once a credible US or Japan structure already exists to reference. Sequence accordingly: don't open all three doors on the same week.
For biotech partnering or asset strategy discussions, contact Kerlann Advisory.